Pyxis Oncology
PYXS | NASDAQ
$1.41
-$0.17 (-10.76%)
At close: Nov 16, 2026, 4:00 PM ET
$1.43
+$0.02 (+1.29%)
After-hours:
Nov 16, 2026, 7:06 PM ET
-10.76%
(1D)No price chart data available for 1D timeframe.
Rating
33.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #701/1021 (Top 69%)
Key Statistics
Market Data
Market Cap $168.65M
1D Range
1.41 1.56
52W Range
1.06 5.34
Valuation (TTM)
PE -1.08
PB 4.08
EV/EBITDA -1.58
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $7.50
Cash Flow
FCF Yield -42.1%
SBC Adj. FCF Yield -48.1%
SBC Impact -14.3%
Margins
Gross Margin 99.8%
Operating Margin -807.8%
FCF Margin -642.6%
Growth (CAGR)
Revenue 3Y | 5Y -25.5% |
41.5%
Dil EPS 3Y | 5Y -9.5% |
23.8%
FCF 3Y | 5Y -13.0% |
6.1%
Returns
ROA -113.0%
ROE -252.4%
ROIC -151.8%
Financial Health
Net Cash
$38.17M
Current Ratio 2.96
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipel...
Sector Healthcare
Industry Biotechnology
Employees 56
IPO Date Oct 8, 2021
Website www.pyxisoncology.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$7.50
Upside
+431.91%
Buy (7)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PYXS